Fairway Medical Technologies Inc.
Fairway Medical Technologies Inc. of
Houston has received $3.8 million in federal funding to conduct Phase II research
on optoacoustic breast and prostate cancer diagnostic methods. The NIH’s National
Cancer Institute has awarded the company $2.7 million to develop its laser-ultrasound-nanotechnology
system for animal tests and a $1.1 million Small Business Innovation Research grant
for the development of a commercial prostate cancer early-detection system. The
laser-based technology is used with gold nanorods bound to antibodies to allow higher
contrast and definition. It has the potential to detect tumors as small as 2 mm
and can differentiate between benign and malignant tumors.
Seno Medical Instruments of San Antonio
has purchased Fairway Medical’s optoacoustic technology and will introduce
it as a real-time breast cancer detection and diagnosis method. The company will
help fund the system’s initial commercialization steps.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024